Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting

Heart

Volumn 97, Issue 15, 2011, Pages 1239-1244

  Bouman, Heleen J ^a,b   Harmsze, Ankie M ^a,c   Van Werkum, Jochem W ^a   Breet, Nicoline J ^a   Bergmeijer, Th O ^a   Ten Cate, Hugo ^b   Hackeng, Christian M ^a   Deneer, Vera H M ^a   Ten Berg, Jurriën M ^a  

^a ST ANTONIUS HOSPITAL   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; CLOPIDOGREL; CYTOCHROME P450 2C19;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CONTROLLED STUDY; CORONARY STENT; DIABETES MELLITUS; DRUG USE; FEMALE; GENDER; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; ON TREATMENT PLATELET REACTIVITY; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION;

AGED; ANGIOPLASTY, BALLOON, CORONARY; ARYL HYDROCARBON HYDROXYLASES; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PREOPERATIVE PERIOD; PROGNOSIS; PROSPECTIVE STUDIES; STENTS; TICLOPIDINE;

EID: 79960160555     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2010.220509     Document Type: Article

References (14)

1. Combescure C, Fontana P, Mallouk N, et al. Clinical implications of clopidogrel non-response in cardiovascular patients: a systematic review and meta-analysis. J Thromb Haemost 2010;8:923-33.
2. Breet NJ, van Werkum JW, Bouman HJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2010;303:754-62.
3. El Ghannudi S, Ohlmann P, Meyer N, et al. Impact of P2Y12 inhibition by clopidogrel on cardiovascular mortality in unselected patients treated by percutaneous coronary angioplasty. A prospective registry. JACC Cardiovasc Interv 2010;3:648-56.
4. Sofi F, Giusti B, Marcucci R, et al. Cytochrome P450 2C19(*)2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis. Pharmacogenomics J 2011;11:199-206.
5. Bonello L, Tantry US, Marcucci R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010;56:919-33.
6. Harmsze AM, Robijns K, van Werkum JW, et al. The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response. Thromb Haemost 2010;103:920-5.
7. Gremmel T, Steiner S, Seidinger D, et al. Calcium- channel blockers decrease clopidogrel-mediated platelet inhibition. Heart 2010;96:186-9.
8. Hochholzer W, Trenk D, Fromm MF, et al. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J Am Coll Cardiol 2010;55:2427-34.
9. Bouman HJ, Parlak E, van Werkum JW, et al. Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel. J Thromb Haemost 2010;8:482-8.
10. van Werkum JW, Hackeng CM, Smit JJ, et al. Monitoring antiplatelet therapy with point-of-care platelet function assays: a review of the evidence. Future Cardiol 2008;4:33-55.
11. Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009;302:849-57.
12. Food and Drug Administration. FDA Drug Safety Communication: reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug, 2010. http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm203888.htm (accessed 10 Dec 2010).
13. Wiviott SD, Braunwald E, Angiolillo DJ, et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation 2008;118:1626-36.
14. Wallentin L, James S, Storey RF, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 2010;376:1320-8.